Search Results
Phase III study shows carfilzomib is an effective addition to standard myeloma therapy
Phase III study shows carfilzomib is an effective addition to standard myeloma therapy
ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy
Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma
Prof Keith Stewart at ASH 2014: Phase 3 study of carfilzomib and anti-CD38 therapy in myeloma
Carfilzomib Use in Multiple Myeloma
Clinical Trials in Multiple Myeloma
Updated Efficacy and Safety Results of the Phase 3 CANDOR study
Myeloma Expert Brian Durie Discusses the ASPIRE Trial
Adding Carfilzomib to R/R Myeloma Regimens
2019 Multiple Myeloma Symposium | Novel and Next Generation Therapy
Results of the ASPIRE trial for MM: the addition of carfilzomib